

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.com

Apollo launches early screening and diagnosis programme for endometrial and ovarian cancers

30 July 2025 | News

End-O Check will provide risk-based assessments, diagnostic testing, and symptom evaluation for women



Reinforcing its commitment to preventive oncology for women, Apollo Cancer Centres (ACCs) has launched End-O Check, a comprehensive early detection programme targeting women aged 45 and above. The initiative is designed to detect two of the most prevalent gynaecologic cancers—endometrial and ovarian—at an early and more treatable stage.

Ovarian cancer, often referred to as the “silent killer,” affects women between 55 and 64 years of age, with the average diagnosis occurring at 63. When caught early, the five-year survival rate exceeds 90%.

In India, the total cancer cases are projected to grow to 1.57 million by 2025, with ovarian and uterine cancers continuing to report among the top five cancers affecting women. The age-standardized incidence rates are estimated at 4.6 per 100,000 for ovarian cancers and 2.5 per 100,000 for corpus uterine cancers. Contributing factors include shifts in reproductive patterns, urban lifestyles, and a rise in metabolic conditions, highlighting the urgent need for targeted detection in high-risk populations.

While endometrial cancer often presents with symptoms such as unexpected bleeding or abnormal discharge, many women fail to report these signs early, leading to delayed diagnosis and poorer outcomes.

End-O Check is designed with a focus on early detection in high-risk populations, symptom awareness, and timely intervention, empowering women to take proactive steps for their gynaecologic health.